GMCI plus Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients

Go Back to All Clinical Trials

GMCI plus Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients

Brief description of study

The purpose of the trial is to assess the safety and efficacy of the Gene Mediated Cytotoxic Immunotherapy (GMCI) added to standard of care immune checkpoint inhibitor (ICI) for non-small Cell Lung Cancer (NSCLC) patients. We want to know if GMCI can increase the number of patients who will respond to the continued ICI. Patents may receive whatever standard of care therapy as indicated by their disease such as maintenance chemotherapy, bevacizumab , or focal radiation.

Clinical Study Identifier: s19-01928

ClinicalTrials.gov Identifier: NCT04495153

Principal Investigator: Daniel H. Sterman.

Other Investigators: Vivek Murthy, Sally Lau, Vamsidhar Velcheti, Samaan Rafeq, Mary Lynn R Nierodzik, Elaine Shum, Marissa Rybstein, Melissa L Martinez, Salman Rafi Punekar, Natalia Cherkassky, Abraham Chachoua, Joshua K Sabari, Jamie L. Bessich, William H. Moore, Lauren G. Khanna, Edna Shifteh, Lea Azour, David Mendoza, Avital Benson, Elsa Bahiru, Jeffrey G Schneider, Cristian C Papazoglu Statescu, Daniel Da Costa, Jessica Wang, Ian John Henderson, Jennifer Wu.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies